PL4337652T3 - Inhibitory NLRP3 - Google Patents

Inhibitory NLRP3

Info

Publication number
PL4337652T3
PL4337652T3 PL22728228.2T PL22728228T PL4337652T3 PL 4337652 T3 PL4337652 T3 PL 4337652T3 PL 22728228 T PL22728228 T PL 22728228T PL 4337652 T3 PL4337652 T3 PL 4337652T3
Authority
PL
Poland
Prior art keywords
nlrp3 inhibitors
nlrp3
inhibitors
Prior art date
Application number
PL22728228.2T
Other languages
English (en)
Inventor
Lea Aurelie BOUCHE
Wolfgang Guba
Georg Jaeschke
Stefanie Katharina MESCH
Andreas Michael TOSSTORFF
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of PL4337652T3 publication Critical patent/PL4337652T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/061,2,4-Triazines
    • C07D253/0651,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/071,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL22728228.2T 2021-05-12 2022-05-10 Inhibitory NLRP3 PL4337652T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP21173452 2021-05-12
EP21209447 2021-11-22
EP21215859 2021-12-20
PCT/EP2022/062525 WO2022238347A1 (en) 2021-05-12 2022-05-10 Nlrp3 inhibitors

Publications (1)

Publication Number Publication Date
PL4337652T3 true PL4337652T3 (pl) 2025-07-14

Family

ID=81941106

Family Applications (1)

Application Number Title Priority Date Filing Date
PL22728228.2T PL4337652T3 (pl) 2021-05-12 2022-05-10 Inhibitory NLRP3

Country Status (25)

Country Link
US (1) US20240208928A1 (pl)
EP (2) EP4337652B1 (pl)
JP (1) JP2024517917A (pl)
KR (1) KR20240007152A (pl)
AR (1) AR125818A1 (pl)
AU (1) AU2022275300A1 (pl)
BR (1) BR112023023527A2 (pl)
CA (1) CA3214626A1 (pl)
CL (1) CL2023003312A1 (pl)
CO (1) CO2023016204A2 (pl)
CR (1) CR20230529A (pl)
DK (1) DK4337652T3 (pl)
ES (1) ES3031704T3 (pl)
FI (1) FI4337652T3 (pl)
HR (1) HRP20250632T1 (pl)
HU (1) HUE071498T2 (pl)
IL (1) IL307188A (pl)
LT (1) LT4337652T (pl)
MA (1) MA64323B1 (pl)
MX (1) MX2023012907A (pl)
PE (1) PE20240126A1 (pl)
PL (1) PL4337652T3 (pl)
RS (1) RS66893B1 (pl)
SI (1) SI4337652T1 (pl)
WO (1) WO2022238347A1 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
IL314025A (en) * 2022-01-07 2024-08-01 Transthera Sciences Nanjing Inc Nlrp3 inflammasome inhibitor and uses thereof
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
IL320499A (en) * 2022-11-04 2025-06-01 Transthera Sciences Nanjing Inc Nlrp3 inflammasome inhibitor and use thereof
KR20250116028A (ko) * 2022-12-07 2025-07-31 에프. 호프만-라 로슈 아게 Nlrp3 억제 조절제로서의 신규 화합물
KR20250137706A (ko) * 2023-01-27 2025-09-18 므윈길 테라퓨틱스 인코포레이티드 Nlrp3 억제제
WO2024193541A1 (en) * 2023-03-20 2024-09-26 Insilico Medicine Ip Limited Nlrp3 inflammasome inhibitors and uses thereof
AU2024240851A1 (en) 2023-03-23 2025-10-16 Chengdu Zenitar Biomedical Technology Co., Ltd. Triazine compound and use thereof
WO2024249539A1 (en) 2023-06-02 2024-12-05 Merck Sharp & Dohme Llc 5,6 unsaturated bicyclic heterocyles useful as inhibitors of nod-like receptor protein 3
IL324489A (en) 2023-06-29 2026-01-01 Hoffmann La Roche Triazine derivatives as NLRP3 inhibitors
WO2025026882A1 (en) 2023-07-28 2025-02-06 F. Hoffmann-La Roche Ag Novel compounds
WO2025059069A1 (en) * 2023-09-12 2025-03-20 Zomagen Biosciences Ltd Nlrp3 modulators
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Nlrp3及glp-1a組合療法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653316B1 (en) * 1999-05-19 2003-11-25 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
UY38687A (es) 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso

Also Published As

Publication number Publication date
SI4337652T1 (sl) 2025-07-31
RS66893B1 (sr) 2025-07-31
LT4337652T (lt) 2025-06-25
CO2023016204A2 (es) 2023-12-11
KR20240007152A (ko) 2024-01-16
EP4609865A2 (en) 2025-09-03
MX2023012907A (es) 2023-11-08
FI4337652T3 (fi) 2025-06-20
DK4337652T3 (da) 2025-06-10
TW202311245A (zh) 2023-03-16
AU2022275300A1 (en) 2023-09-21
HUE071498T2 (hu) 2025-09-28
US20240208928A1 (en) 2024-06-27
BR112023023527A2 (pt) 2024-01-30
JP2024517917A (ja) 2024-04-23
EP4337652B1 (en) 2025-04-09
EP4609865A3 (en) 2025-10-29
MA64323B1 (fr) 2025-06-30
PE20240126A1 (es) 2024-01-22
EP4337652A1 (en) 2024-03-20
HRP20250632T1 (hr) 2025-07-18
IL307188A (en) 2023-11-01
ES3031704T3 (en) 2025-07-10
CA3214626A1 (en) 2022-11-17
WO2022238347A1 (en) 2022-11-17
CL2023003312A1 (es) 2024-06-21
CR20230529A (es) 2023-12-04
AR125818A1 (es) 2023-08-16

Similar Documents

Publication Publication Date Title
SI4337652T1 (sl) Zaviralci NLRP3
IL287042A (en) Inflammatory inhibitors of nlrp3
IL280336A (en) NLRP3 inflammasome inhibitors
IL309680A (en) NLRP3 inflammasome inhibitors
EP4262807A4 (en) Azachinazoline pan-KRAS inhibitors
IL309118A (en) CDK2 inhibitors
IL313727A (en) Parfee inhibitors
IL318258A (en) NLRP3 inflammasome inhibitors
IL315027A (en) Inhibitors of nlrp3
IL314049A (en) PARP7 inhibitors
GB202008201D0 (en) Inhibitor compounds
IL318533A (en) NLRP3 inflammasome inhibitors
GB202004960D0 (en) Inhibitor compounds
GB202110373D0 (en) Inhibitor compounds
IL315980A (en) EGFR inhibitors
SI4323338T1 (sl) Zaviralci TEAD
PT4337652T (pt) Inibidores do nlrp3
EP4263533C0 (en) Erap inhibitors
IL320219A (en) Inhibitors
IL313756A (en) Inhibitors of the sestrin-MAPK complex
HK40061653A (zh) Nlrp3炎性小体抑制剂
IL325676A (en) Kat6 inhibitors
HK40122649A (en) Nlrp3 inhibitors
GB202117224D0 (en) Inhibitor compounds
GB202112240D0 (en) Inhibitor compounds